<DOC>
	<DOCNO>NCT01062477</DOCNO>
	<brief_summary>The purpose study assess immunogenicity safety ACTACEL combine vaccine support registration product China Primary Objectives : - To demonstrate ACTACEL vaccine administer 2 , 3 4 month age 3 , 4 5 month age inferior , term seroprotection , Wuhan 's Diphtheria , Tetanus , acellular Pertussis ( DTaP ) Haemophilus influenzae type b ( Act-HIB ) vaccine give concomitantly , diphtheria , tetanus , Polyribosyl Ribitol Phosphate ( PRP ) antigens , one month three-dose primary vaccination . - To demonstrate superiority , term seroconversion , ACTACEL vaccine administer 2 , 3 4 month age 3 , 4 5 month age Pertussis Toxoid ( PT ) , Fimbriae type 2 3 ( FIM2 ) ( FIM3 ) pertussis antigen , compare Wuhan 's DTaP Act-HIB vaccine give concomitantly , one month three-dose primary vaccination . Secondary Objectives : - To describe safety administration study vaccine . - To describe group immunogenicity study vaccine one month primary vaccination one month booster vaccination .</brief_summary>
	<brief_title>A Study DTaP//PRP-T Combined Vaccine ( ACTACEL ) Versus Local DTaP Act-HIB Monovalent Vaccine Healthy Infants</brief_title>
	<detailed_description>Participants receive primary vaccination consist three dos ACTACEL either 2 , 3 , 4 month age 3 , 4 , 5 month age ; Wuhan DTaP Act-HIB vaccine 3 , 4 , 5 month age . All participant receive single booster dose 18-20 month age follow one month last dose study vaccine .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 2 month day inclusion Born full term pregnancy ( ≥ 36 week ) birth weight ≥ 2.5 kg Informed consent form sign parent ( ) legal representative Participant parent/legal representative able attend schedule visit comply trial procedure Exclusion Criteria : Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy since birth , longterm systemic corticosteroid therapy Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance Chronic illness stage could interfere trial conduct completion , opinion Investigator Receipt blood bloodderived product since birth might interfere assessment immune response Receipt plan receipt vaccine 4 week precede follow trial vaccination ( except oral poliovirus ( OPV ) , bacillus CalmetteGuérin ( BCG ) , Hepatitis B vaccine give within 8 day study vaccination ) History seizure Known personal maternal Human Immunodeficiency Virus ( HIV ) , Hepatitis B ( HB ) surface antigen Hepatitis C seropositivity History diphtheria , tetanus , pertussis Haemophilus influenzae type b infection ( confirm either clinically , serologically microbiologically ) Previous vaccination diphtheria , tetanus , pertussis Haemophilus influenzae type b disease either trial vaccine another vaccine Participant high risk diphtheria , tetanus , pertussis Haemophilus influenzae type b infection trial Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion contraindicate intramuscular vaccination History contraindication vaccination pertussiscontaining vaccine Febrile illness ( axillary temperature ≥37.1°C ) moderate severe acute illness/infection day inclusion , accord Investigator judgment Temporary contraindication must resolve vaccination : Acute febrile illness within 72 hour precede vaccination , temperature ≥37.1°C present visit Any vaccination 4 week precede vaccination ( except OPV , BCG , hepatitis B vaccine give within 8 day study vaccination ) Systemic corticosteroid therapy ( prednisone equivalent ) 2 consecutive week within past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>60 Days</minimum_age>
	<maximum_age>89 Days</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Diphtheria Tetanus Pertussis Haemophilus Influenzae Type B</keyword>
</DOC>